论文部分内容阅读
升白新是北京制药工业研究所于1973年研制成功的一种新药;该药由草药山荷叶中提取其有效成份后,经半合成而制得。升白新对实验动物有明显的升白细胞作用,且毒性低,治疗指数大,经临床初步试用表明,升白新对用一般药物难以奏效的原因不明性粒细胞减少症,具有一定的疗效;对放疗、化疗所致的白细胞减少症,也有较好的升白细胞作用。但在以往临床试用中,均采用口服给药,而吸收很不完全,约有50%自粪中排出体外;而在肌注给药实验中表明,吸收快而完全,血药浓度的高峰出现早,持续时间长。为适应今后临床改用肌注给药,以提高疗效,节约药品,我们研究了升白新肌注亚急性毒性。
Shengbaixin is a new drug developed by the Beijing Institute of Pharmaceutical Industry in 1973. This drug is obtained by semi-synthesizing the active ingredients extracted from the lotus leaves of the herbs. Shengbaixin has obvious leukocyte-inducing effects on experimental animals, and has low toxicity and treatment index. Preliminary clinical trials have shown that Shengbaixin has certain curative effect on the unexplained neutropenia caused by general drugs; Leukopenia, caused by chemotherapy, also has a beneficial effect on leukoreduction. However, in the past clinical trials, oral administration was used, and absorption was incomplete. About 50% was excreted from the feces; in the intramuscular injection experiment, absorption was rapid and complete, and peak plasma concentrations appeared. Early, long duration. In order to adapt to the clinical use of intramuscular injection in order to improve the efficacy and save drugs, we studied the subacute toxicity of intramuscular injection of Shengbaixin.